Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multiple sclerosis, emerging epidemiological trends and redefining the clinical course

  • Portaccio, Emilio
  • Magyari, Melinda|||0000-0002-0972-5222
  • Kubala Havrdova, Eva|||0000-0002-9543-4359
  • Ruet, Aurelie
  • Brochet, Bruno
  • Scalfari, Antonio
  • Di Filippo, Massimiliano
  • Tur, Carmen|||0000-0003-1849-3184
  • Montalban, Xavier|||0000-0002-0098-9918
  • Amato, Maria Pia|||0000-0003-3325-3760
Multiple sclerosis is a chronic, inflammatory, and neurodegenerative disease of the central nervous system and a major cause of neurological disability in young adults. Its prevalence and incidence are increasing, and it has been estimated at over 2.8 million cases worldwide, in addition to recent trends towards a shift in MS prevalence to older ages, with peak prevalence estimates in the sixth decade of life. Although historically the relapsing and progressive phases of the disease have been considered separate clinical entities, recent evidence of progression independent of relapse activity (PIRA) has led to a reconsideration of multiple sclerosis as a continuum, in which relapsing and progressive features variably coexist from the earliest stages of the disease, challenging the traditional view of the disease course. In this Series article, we provide an overview of how the traditional description of the clinical course of MS and epidemiological trends in Europe have evolved. For this purpose, we focus on the concept of PIRA, discussing its potential as the main mechanism by which patients acquire disability, how its definition varies between studies, and ongoing research in this field. We emphasise the importance of incorporating the assessment of hidden clinical manifestations into patient management to help uncover and quantify the PIRA phenomenon and the possible implications for future changes in the clinical classification of the disease. At the same time, we provide insights into overcoming the challenges of identifying and defining PIRA and adopting a new understanding of the clinical course of MS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Deep learning to predict progression independent of relapse activity at a first demyelinating event

  • Coll, Llucia|||0000-0003-2224-1246
  • Pareto, Deborah|||0000-0001-7356-3769
  • Aparicio Serrano, Francisco
  • Otero-Romero, Susana|||0000-0002-6798-568X
  • Cobo-Calvo, Álvaro|||0000-0002-2574-0721
  • Reinders, Evy
  • Alberich, Manel|||0000-0002-4132-0620
  • Arévalo, María Jesús|||0000-0003-0626-5555
  • Arrambide, Georgina|||0000-0002-2657-5510
  • Auger, Cristina|||0000-0001-9846-4767
  • Castilló, Joaquín|||0000-0002-8951-6315
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Galan, Ingrid|||0000-0001-5774-4260
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Nos, Carlos|||0000-0002-3830-4910
  • Novak, Frederik
  • Oliver, Arnau
  • Río, Jordi|||0000-0003-4546-7627
  • Rodríguez Acevedo, Breogán|||0000-0002-0314-753X
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Zabalza, Ana|||0000-0003-3860-5251
  • Montalban, Xavier|||0000-0002-0098-9918
  • Rovira, Alex|||0000-0002-2132-6750
  • Tintoré, Mar|||0000-0001-9999-5359
  • Lladó, Xavier
  • Tur, Carmen|||0000-0003-1849-3184
Progression independent of relapse activity is the main cause of irreversible disability in multiple sclerosis and is strongly associated with older age at symptom onset. Early and accurate prediction, at symptom onset, of which patients are at highest risk of progression independent of relapses, is an unmet need. This study aimed to develop a deep learning survival model using only routine MRI acquired at the first demyelinating attack to predict the risk of progression independent of relapses, and assess its ability to improve classical age-adjusted predictions. We analysed a prospective cohort of patients under 50, clinically assessed within three months of symptom onset, with available MRI (T1- and T2-Fluid-Attenuated Inversion Recovery sequences). An independent early multiple sclerosis cohort (≤1 year from symptom onset) from the Multiple Sclerosis Partners Advancing Technology and Health Solutions database (N = 32) was used for external validation. Patients were assessed for progression independent of relapse activity, defined as a 6-month confirmed increase in the Expanded Disability Status Scale without relapses. Our deep learning model used EfficientNet to estimate the cumulative probability of progression independent of relapses at 1-year intervals. We employed 5-fold cross-validation for model training and testing, assessing performance with the time-dependent concordance index. We also investigated the optimal cumulative probability threshold for binary risk stratification. The model's ability to improve a classical Cox regression model was evaluated. Additionally, we identified brain regions most relevant to deep learning-based progression independent of relapse activity predictions using an interpretability algorithm. A total of 259 patients were evaluated, 58 (22%) of whom experienced at least one event of progression independent of relapse activity over a median follow-up of 4.2 years. The deep learning model demonstrated high performance (time-dependent concordance index = 0.72) with an accuracy of 78% in the original cohort and 72% in the external cohort for predicting the risk of progression independent of relapse activity. Incorporating the deep learning-derived cumulative probability of progression independent of relapses significantly improved an age-adjusted Cox regression model, raising Harrell's C index from 0.62 to 0.74. Interpretability revealed the frontoparietal cortex as a key region in predicting progression independent of relapse activity. In conclusion, our deep learning survival model, based on routine MRI at the first demyelinating attack, can accurately identify patients at high risk of progression independent of relapses and may serve as a valuable tool in clinical practice.